Acute coronary syndrome
Conditions
Interventions
Experimental group:Secondary Prevention of Coronary heart Disease + Suxiaojiuxin Pills (5 tablets, P.O. TID)
Control group:Secondary prevention of coronary heart disease + placebo (5 tablets, P.O. TID)
Sponsors
Guangdong Provincial Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of acute coronary syndrome and qi stagnation and blood stasis syndrome at the same time; 2. Aged 30 to 75 years; 3. The patients themselves or their families agree to participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Permanent severe arrhythmia: III degree atrioventricular block, sick sinus syndrome; 2. After cardiac arrest and CPR; 3. Severe heart failure: New York heart function class III-IV; 4. Acute cerebrovascular disease (ischemic stroke, hemorrhagic stroke); 5. Patients with severe blood system diseases (hemophilia, severe anemia, thrombocytopenic purpura, essential thrombocythemia); 6. Severe renal insufficiency (serum creatinine level >=265umol/L); 7. Severe liver disease (cirrhosis or liver cancer), liver function damage (serum alanine aminotransferase/aspartate aminotransferase > 3 times the upper limit of normal); 8. Gastrointestinal surgery may affect drug absorption; 9. Malignant tumor or life expectancy <= 2 years; 10. Mental disorder or mental retardation; 11. Patients who need coronary artery bypass grafting (heart bypass); 12. Allergic to known components of the test drug; 13. Severe respiratory diseases such as severe chronic obstructive pulmonary disease, severe pulmonary hypertension, and pulmonary embolism; 14. Women who are breastfeeding or pregnant, or women of childbearing age who plan to become pregnant within 6 months after the screening examination, or those who have a positive urine pregnancy test; or male patients who plan to give birth or donate sperm; 15. Suspect or have a history of alcohol or drug abuse; 16. Patients who have participated in clinical trials of other drugs within 3 months before the screening examination; 17. Other patients deemed unsuitable by the investigator to participate in this study; 18. Long-term oral anticoagulants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| endothelium dependent dilation; | — |
Secondary
| Measure | Time frame |
|---|---|
| endothelium independent dilation;Major Adverse Cardiovascular Events;Seattle Angina scale score;Traditional Chinese Medicine syndrome integral; | — |
Countries
China
Contacts
Public ContactChen Bojun
Guangdong Provincial Hospital of Traditional Chinese Medicine
Outcome results
None listed